Sun Pharma looks to shine with tiny deals

Its subsidiary Taro's acquisition of Thallion Pharma is ninth acquisition since buying Ranbaxy

Sun Pharmaceutical’s subsidiary, Taro, made a tiny acquisition of Thallion Pharmaceuticals for $1.7 million in Canada on March 17. It was the ninth acquisition by Sun Pharma and its subsidiaries in the previous two years since it made a $4.2-billion big-bang acquisition of Ranbaxy Laboratories in 2015.

Till the acquisition of Ranbaxy, the company had made only seven acquisitions in 18 years, including Taro Pharma in Israel in 2010. The first was in 1997, when it acquired US-based Caraco for $37.5 million. This gave the Dilip Shanghvi-promoted company an entry into the lucrative US markets.

“With the Ranbaxy acquisition, Sun